Not applicableEnded earlyNCT02932345What this trial is testingGefitinib Long-term Survivor StudyWho this might be right forEGFR Mutation Positive Advanced Non-small-cell Lung Cancer AstraZeneca 59
Testing effectiveness (Phase 2)Looking for participantsNCT05334277What this trial is testingFurmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNAWho this might be right forNon-small Cell Lung Cancer Sun Yat-sen University 280
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992What this trial is testingAlflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）Who this might be right forLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer Allist Pharmaceuticals, Inc. 358
Large-scale testing (Phase 3)Study completedNCT01814553What this trial is testingADAM-Afatinib Diarrhea Assessment and ManagementWho this might be right forCarcinoma, Non-Small-Cell Lung Boehringer Ingelheim 40
Not applicableLooking for participantsNCT05598528What this trial is testingExploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)Who this might be right forLung Cancer, Non-small CellEGFR Gene MutationEGFR-TKI Resistant Mutation+2 more Second Xiangya Hospital of Central South University 210
Early research (Phase 1)Study completedNCT02228369What this trial is testingOral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerWho this might be right forEGFR Mutation Positive Advanced Non Small Cell Lung Cancer AstraZeneca 108
Testing effectiveness (Phase 2)UnknownNCT03341494What this trial is testingEGFR Mutation Positive NSCLC Patients With Gefitinib and ThalidomideWho this might be right forNSCLC Stage IVChemotherapy Effect Fujian Cancer Hospital 128
Large-scale testing (Phase 3)UnknownNCT03008109What this trial is testingEndostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLCWho this might be right forAdvanced CancerLung Cancer, Nonsmall Cell Zaiwen Fan 80
Testing effectiveness (Phase 2)Study completedNCT03861156What this trial is testingD-0316 in Patients With EGFR Positive Non Small Cell Lung CancerWho this might be right forSolid TumorNSCLCEGFR T790M InventisBio Co., Ltd 290
Testing effectiveness (Phase 2)UnknownNCT02725918What this trial is testingPemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs FailureWho this might be right forNon-small Cell Lung Cancer Guangdong Association of Clinical Trials 150
Testing effectiveness (Phase 2)Looking for participantsNCT06775743What this trial is testingORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIsWho this might be right forNSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer Fudan University 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229What this trial is testingOsimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibWho this might be right forCarcinoma AstraZeneca 367
Not applicableStudy completedNCT03133234What this trial is testingEffect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLCWho this might be right forT790M Positive NSCLC Patients AstraZeneca 47
Not applicableStudy completedNCT04640870What this trial is testingThe Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With AfatinibWho this might be right forNon Small Cell Lung CancerEGF-R Positive Non-Small Cell Lung CancerEGFR Gene Mutation Hellenic Cooperative Oncology Group 59
Large-scale testing (Phase 3)Study completedNCT02474355What this trial is testingReal World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLCWho this might be right forLung Cancer AstraZeneca 3,017
Testing effectiveness (Phase 2)Active Not RecruitingNCT04504071What this trial is testingDacomitinib in Lung Cancer With Uncommon EGFR MutationsWho this might be right forNon-small Cell Lung Cancer MetastaticEGF-R Positive Non-Small Cell Lung Cancer Shanghai Chest Hospital 30
Testing effectiveness (Phase 2)UnknownNCT03126799What this trial is testingTarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)Who this might be right forEGFR Positive Non-small Cell Lung Cancer National Cancer Center, Korea 128
Testing effectiveness (Phase 2)Study completedNCT01513174What this trial is testingStudy With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib AloneWho this might be right forNon Small Cell Lung Cancer Spanish Lung Cancer Group 186
Not applicableActive Not RecruitingNCT03969823What this trial is testingWhole Genomic Landscape of Advanced EGFR-mutant NSCLCWho this might be right forLocally Advanced or Metastatic NSCLC Seoul National University Hospital 148
Testing effectiveness (Phase 2)Study completedNCT01530334What this trial is testingIressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous TreatmentWho this might be right forLung Cancer AstraZeneca 61